Country: অস্ট্রেলিয়া
ভাষা: ইংরেজি
সূত্র: Department of Health (Therapeutic Goods Administration)
Amoxycillin trihydrate; Potassium clavulanate
Sandoz Pty Ltd
Medicine Registered
CURAM ® 125/31.25 AMOXYCILLIN (AS TRIHYDRATE) AND CLAVULANIC ACID (AS POTASSIUM CLAVULANATE) 125MG+31.25MG/5ML POWDER FOR ORAL SUSPENSION _ _ CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Curam 125/31.25. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of your child taking this medicine against the benefits they expect it will have. IF YOU HAVE ANY CONCERNS ABOUT YOUR CHILD TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CURAM 125/31.25 IS USED FOR This medicine is used to treat a wide range of infections caused by bacteria. These infections may affect:_ _ • the chest (bronchitis or pneumonia) • the bladder (cystitis) • the sinuses (sinusitis) • the ears (otitis media) • or the skin. It works by killing the bacteria that cause these infections. This medicine contains the active ingredients amoxycillin (as trihydrate) and clavulanic acid (as potassium clavulanate). Amoxycillin belongs to the penicillin group of antibiotics. Clavulanic acid is used to increase the effectiveness of amoxycillin against certain types of bacteria. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOUR CHILD. Your doctor may have prescribed it for another reason. _ _ There is no evidence that this medicine is addictive. This medicine is available only with a doctor’s prescription. BEFORE YOU GIVE CURAM 125/31.25 _WHEN YOU MUST NOT GIVE IT _ DO NOT GIVE THIS MEDICINE IF YOUR CHILD HAS AN ALLERGY TO: Curam ® 125/31.25 1 • amoxycillin trihydrate or potassium clavulanate, the active ingredients, or to any of the other ingredients listed at the end o সম্পূর্ণ নথি পড়ুন